MiNK Therapeutics (NASDAQ:INKT) Issues Quarterly Earnings Results

MiNK Therapeutics (NASDAQ:INKT) announced its earnings results on Wednesday. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.16, Zacks reports. The company had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.07 million.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK has initiated a randomized Phase II ARDS trial enrolling 90 patients, comparing agenT-797 plus standard care with placebo plus standard care. The company says the protocol could transition seamlessly to Phase III, with preliminary data targeted for the second half of 2026; endpoints include survival and ventilator-free days.
• Management highlighted Phase II gastric cancer results in which median overall survival exceeded 23 months in an immune-primed cohort, with some patients still alive years after treatment. These are company-cited observations from a heavily pretreated population, and follow-up is ongoing.
• MiNK reported that the same agenT-797 product showed different immune activity in cancer and ARDS patient analyses, and said it is evaluating biomarkers that may help identify patients most likely to respond. The findings are early translational evidence, not proof of clinical benefit in the randomized trial.
• MiNK ended the first quarter with approximately $9.5 million in cash, after repaying about $5.2 million of debt and raising roughly $3 million through an at-the-market offering. Management expects at least 12 months of runway, including the ARDS trial, while the cash balance and ATM financing indicate continued funding needs may remain relevant.

MiNK Therapeutics Stock Performance

NASDAQ:INKT traded up $0.06 during trading hours on Friday, hitting $9.59. The stock had a trading volume of 11,760 shares, compared to its average volume of 99,274. The business’s 50 day moving average is $11.14 and its 200-day moving average is $11.21. The company has a market cap of $48.88 million, a price-to-earnings ratio of -4.26 and a beta of 0.49. MiNK Therapeutics has a one year low of $8.48 and a one year high of $16.93.

Analyst Ratings Changes

INKT has been the subject of a number of research reports. Zacks Research lowered shares of MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Friday, October 2nd. B. Riley Financial reiterated a “buy” rating and issued a $50.00 price target (up from $43.00) on shares of MiNK Therapeutics in a report on Wednesday, October 21st. Finally, HC Wainwright started coverage on shares of MiNK Therapeutics in a research note on Wednesday, November 4th. They set a “buy” rating and a $38.00 price target for the company. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $44.00.

Insider Activity

In related news, CEO Jennifer Buell sold 6,938 shares of the company’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the sale, the chief executive officer owned 74,195 shares in the company, valued at $783,499.20. This represents a 8.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 20.40% of the stock is owned by company insiders.

About MiNK Therapeutics

MiNK Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses. MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.